Pradaxa is an oral anticoagulant medication used to prevent blood clots. Its active ingredient, dabigatran etexilate, directly inhibits the clotting enzyme thrombin. By blocking thrombin it prevents the conversion of fibrinogen to fibrin, thereby decreasing clot formation. The drug is prescribed to lower the risk of stroke in patients with nonvalvular atrial fibrillation. It is also employed to treat and prevent deep vein thrombosis and pulmonary embolism after major orthopedic procedures. Absorption occurs rapidly in the gastrointestinal tract and the compound distributes throughout plasma and extravascular compartments. The medication is eliminated mainly by the kidneys, which influences its duration of action.

Pradaxa is a direct thrombin inhibitor prescribed for stroke prevention in patients with atrial fibrillation. The drug is classified as an oral anticoagulant that selectively binds to the active site of thrombin. By inhibiting thrombin it reduces the conversion of fibrinogen to fibrin thereby limiting clot formation. This interaction selectively impairs the coagulation cascade without affecting other pathways. The resulting anticoagulant effect helps maintain blood fluidity and lowers the risk of thromboembolic events. Pradaxa is formulated as a capsule that is absorbed consistently across the gastrointestinal tract. Its pharmacokinetic profile features predictable absorption and elimination supporting steady anticoagulation.

Pradaxa may increase the risk of bleeding due to its anticoagulant effect. Some patients experience easy bruising without a clear cause. Gastrointestinal discomfort such as indigestion or abdominal pain has been reported. Headache is a frequently observed symptom in clinical studies. Nausea can occur, especially during the initial period of treatment. A mild reduction in hemoglobin levels may lead to anemia in certain individuals. Elevated liver enzyme measurements are occasionally noted during therapy. Swelling of the lower extremities has been documented in some patients.

Pradaxa may cause bleeding events due to its anticoagulant effect. Common gastrointestinal disturbances include dyspepsia and nausea. Headache and dizziness are frequently reported central nervous system reactions. Edema of the lower extremities can occur as a peripheral response. Skin rashes may develop as an allergic manifestation. Laboratory monitoring sometimes shows elevated liver enzymes.